A Prospective Phase 2 Trial of Reirradiation With Stereotactic Body Radiation Therapy Plus Cetuximab in Patients With Previously Irradiated Recurrent Squamous Cell Carcinoma of the Head and NeckJohn A. Vargo, Dwight E. Heron, Robert L. Ferris et al.|International Journal of Radiation Oncology*Biology*Physics|2015Cited by 156
Risk of Severe Toxicity According to Site of Recurrence in Patients Treated With Stereotactic Body Radiation Therapy for Recurrent Head and Neck CancerDiane C. Ling, Dwight E. Heron, Jonas T. Johnson et al.|International Journal of Radiation Oncology*Biology*Physics|2016Cited by 70
Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancerAthanassios Argiris, Robert L. Ferris, Julie E. Bauman et al.|Annals of Oncology|2016Cited by 49
Phase II trial of post-operative radiotherapy with concurrent cisplatin plus panitumumab in patients with high-risk, resected head and neck cancerRobert L. Ferris, Athanassios Argiris, J.L. Geiger et al.|Annals of Oncology|2016Cited by 34
Long-Term Patient-Reported Quality of Life After Stereotactic Body Radiation Therapy for Recurrent, Previously-Irradiated Head and Neck CancerJoel Thomas, Dwight E. Heron, Hong Wang et al.|Frontiers in Oncology|2020Cited by 11